Biometric firm BIO-key's Q3 loss widens on absence of large orders

BIO-key International

14/11/2025 13:39

Overview

BIO-key Q3 2025 revenue declines to $1.55 mln, missing analyst expectations

Company's Q3 net loss widens to $964,849 from $738,959 in Q3 2024

BIO-key expects strong year-end, driven by European and Middle Eastern markets

Outlook

BIO-key expects full-year 2025 revenue between $6.5 mln and $7 mln

Company anticipates strong growth in 2026 driven by defense spending

BIO-key plans cost reductions to support positive cash flow and profitability

Result Drivers

REVENUE DECLINE - Decrease attributed to absence of large orders from two major customers in Q3'24

SAAS MODEL IMPACT - Transition to SaaS model causes variability in revenue recognition

DEFENSE SECTOR DEPLOYMENT - New deployment in Middle East defense sector expected to drive growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$1.55 mln
$1.80 mln (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the electronic equipment & parts peer group is "buy"

Wall Street's median 12-month price target for BIO-Key International Inc is $2.00, about 51.5% above its November 13 closing price of $0.97

Press Release: ID:nGNX7gsHBX

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)